Bruker Corporation — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing; the supplied text does not provide a clear standalone fourth-quarter income statement. Bruker develops and sells scientific instruments, analytical and diagnostic solutions, and superconducting materials across life science, materials science, diagnostics, and research markets.
Financial performance
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $2,417.9 million | $1,987.5 million | +21.7% |
| Gross profit / margin | $1,209.6 million / 50.0% | $939.8 million / 47.3% | Margin +2.7 percentage points |
| Operating income / margin | $413.3 million / 17.1% | $248.3 million / 12.5% | +66.5% income |
| Net income attributable to Bruker | $277.1 million | $157.8 million | +75.6% |
| Diluted EPS | $1.81 | $1.02 | +$0.79 |
| Cash from operations | $282.4 million | $332.2 million | −$49.8 million |
| Free cash flow (non-GAAP) | $190.4 million | $235.0 million | −19% |
Revenue growth included approximately $43.3 million from currency translation and $8.1 million from acquisitions; organic revenue increased $379.0 million. Management attributed stronger results primarily to broad demand recovery, higher volumes, operating leverage, and favorable product mix. Non-GAAP operating margin rose to 19.4% from 16.0%.
Segments and demand
- BSI Life Science: Revenue of $1,510.6 million, up 20.5%; operating income of $385.4 million versus $273.8 million.
- BSI Nano: Revenue of $697.5 million, up 25.4%; operating income of $73.4 million versus $23.6 million.
- BEST: Revenue of $223.8 million, up 18.1%; operating income of $22.2 million versus $6.2 million.
Demand improved across major product lines and end markets. BSI Nano benefited from industrial and academic recovery and continued semiconductor and microelectronics demand; BEST cited higher “big science” project revenue and recovery in healthcare MRI superconductors.
Cash, liquidity, and debt
- Cash, cash equivalents, and short-term investments totaled $1,168.2 million at year-end, compared with $731.8 million a year earlier. $646.9 million was held outside the United States.
- Total debt was $1,334.2 million, versus $844.5 million in 2020; $112.4 million was current. The increase mainly reflects $492.8 million of proceeds from 2021 senior notes.
- Bruker had $599.8 million available under its $600 million revolving credit facility and reported compliance with debt covenants. It reported no off-balance-sheet arrangements.
- Operating cash flow fell as receivables, inventory, and tax-payment timing absorbed cash. Investing cash outflow was $192.4 million, including $92.0 million of capital expenditures and $65.0 million for acquisitions.
- Management expected existing cash, investments, and credit facilities to cover operating and investing needs for at least twelve months. Planned 2022 capital expenditures were approximately $115 million.
Outlook, risks, and notable items
- Backlog was approximately $2,077.2 million at year-end, up from $2,006.7 million. Management expected about 70% to be recognized as revenue in 2022; backlog is not presented as a reliable long-term revenue indicator.
- Management identified COVID-19 impacts, component shortages and delays, inflation, and geopolitical tensions as risks to manufacturing, costs, demand, and revenue timing. The filing specifically noted Russia’s incursion into Ukraine and potential related sanctions and disruption.
- Foreign sales represented approximately 75% of revenue. Currency translation increased 2021 revenue by about 2.2%; foreign-currency movements remain a source of earnings and equity volatility.
- The annual dividend was $0.16 per share in 2021. Bruker targeted $0.20 annually beginning in 2022 and announced a $0.05 quarterly dividend, subject to Board approval of future payments. It repurchased $153.3 million of shares during 2021 and had $374.9 million of 2021-program authorization remaining as of February 23, 2022.
- 2021 unusual charges included $6.1 million of acquisition-related charges, $4.8 million of restructuring costs, and $2.8 million of IT transformation costs. The effective tax rate was 28.7%, versus 28.5% in 2020; additional uncertain-tax-position reserves contributed to the increase.
- The filing reported ongoing ordinary-course litigation, including a German patent claim brought by Carl Zeiss against subsidiary Luxendo; Bruker said it was vigorously defending the matter and recorded no material accrual. Management said pending matters were not expected to have a material financial impact.
- The auditor identified the BSI Nano goodwill impairment assessment as a critical audit matter, citing judgment involved in forecasting revenue growth. No goodwill impairment was recorded in 2021.
Key facts for investors to verify
- Whether backlog converts as expected, particularly the stated 70% anticipated for 2022, given installation delays and supply constraints.
- Whether operating cash flow recovers as receivables and inventory normalize; free cash flow declined despite sharply higher earnings.
- Debt maturity, covenant headroom, and the effect of the rise in total debt and the 2021 note issuance on future financing flexibility.
- The persistence of margin gains amid inflation, supply-chain costs, and higher labor and logistics expenses.
- Progress on acquisition integration and the assumptions supporting BSI Nano goodwill valuation.
- Potential effects of COVID-19, geopolitical developments and sanctions, foreign exchange movements, and tax exposures on results and liquidity.